MYCN and neuroblastoma: They analyzed an RNA-seq data set from 498 primary NB samples, and they found that miR-186-5p was down-regulated in patients with high risk, N-myc amplified and stage 4 NB, compared to those with low risk, N-myc single copy and stage 1–3 NB.